Suboptimal glycaemic control in primary care: Is the need for intensification of therapy recognised?

Practical Diabetes International

Volumn 25, Issue 7, 2008, Pages 269-272

  Rosindale, Samantha ^a,b   Lockett, Helen ^a   Bromige, Robert ^c   Darby, Adeltrude ^c   Dyer, Robert ^a  

^a TORBAY HOSPITAL   (United Kingdom)

^b Paignton Hospital   (United Kingdom)

^c Compass House Medical Practice ^*  (United Kingdom)

Author keywords

Assessment for insulin; Closer liaison between primary and secondary care; Intensification of diabetes control not always recognised; Suboptimal control; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; DIABETES CONTROL; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; GENERAL PRACTICE; HEALTH CARE NEED; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE PLANNING; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 58049090217     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1272     Document Type: Article

References (10)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
2. UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
3. Phillips P. Type 2 Diabetes - Failure, Blame and Guilt in the Adoption of Insulin Therapy. Rev Diabet Stud 2005; 2(1): 35-39.
4. Turner RC, Cull CA, Frighi V, et al. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281(21): 2005-2012.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385-411.
6. Management of type 2 diabetes - Managing blood glucose levels (Guideline G). London: National Institute for Clinical Excellence, 2002.
7. Wright A, Cull C, Holman R, et al. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128(3): 165-175.
8. Shepherd M, Frost J, Jones J, et al. Insulin initiation in primary care: helping it happen. Diabetes and Primary Care 2007; 9(3):152-158.
9. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
10. DeFronzo RA. Pharmacological therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131(4): 281-303.